Scott Gettinger

Scott Gettinger has been at the forefront of nivolumab development in lung cancer and contributed to investigations elucidating why PD-L1 selection failed to enhance outcomes in the first-line CheckMate-026 trial. His laboratory research examines T-cell exhaustion, immune resistance mechanisms, and novel combination strategies to overcome immunotherapy resistance in NSCLC. He has co-authored seminal long-term follow-up studies for nivolumab in NSCLC and participates in multi-institution first-line IO clinical trials. Gettinger continues to advance understanding of tumor-immune interactions in thoracic malignancies.